Accelerating Cancer Care with Oncology Prior Authorization Automation

Klivira delivers end-to-end **oncology prior authorization automation**, transforming a high-volume, complex workflow into a streamlined process that accelerates patient access to critical cancer treatments.

Oncology workflows present unique challenges for prior authorization, from the urgency of treatment initiation to the complexity of multi-drug regimens and frequent changes. Revenue cycle directors and PA coordinators face immense pressure to manage dozens of PA events per patient across medical and pharmacy benefits, often delaying critical care. Klivira's platform is engineered to address these specific operational demands.

The Unique Demands of Oncology Prior Authorization

Oncology prior authorization is characterized by its high volume and intricate clinical nuances. A single patient may require 10–20 prior authorization events over their treatment course, spanning diagnosis, staging, treatment initiation, regimen changes, and supportive care. The urgency of treatment for many aggressive cancers means PA delays directly impact patient outcomes, demanding an efficient, automated approach.

Key PA Triggers in Oncology

HCPCS J-codes for chemotherapy and biologic infusions (immunotherapies, targeted therapies, antibody-drug conjugates)
Advanced imaging for staging and surveillance (PET/CT, advanced MRI, tumor-specific molecular imaging)
Radiation oncology procedures (IMRT, IGRT, SBRT, brachytherapy, proton-beam therapy CPT ranges)
Genetic and molecular testing (NGS panels, single-gene tests, hereditary cancer panels)
High-cost specialty oral oncolytics and supportive care medications (growth factors, antiemetics, bone-targeting agents)

Navigating Complex Documentation and Payer Policies

Oncology prior authorizations require extensive clinical documentation, often guided by the NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium. Payers demand detailed evidence, from pathology reports and tumor staging (AJCC TNM) to molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1, BRCA, MSI/MMR) and prior-line treatment responses. Denials frequently occur due to documentation gaps, off-label use without compendium support, or step therapy requirements, necessitating robust appeal pathways.

Common Oncology PA Documentation Requirements

Diagnosis confirmation (pathology, histology, AJCC TNM staging, relevant molecular markers)
Prior-line treatment response and rationale for next regimen
Performance status (ECOG or Karnofsky score), comorbidities, and contraindications
For off-label use: NCCN Compendium citation (Category 1, 2A, 2B) with specific clinical context
For radiation oncology: Prescribed dose/fractionation, target volume rationale, organ-at-risk constraints
For genetic testing: Clinical question, testing methodology, and actionability of results

Klivira's Tailored Approach to Oncology PA Automation

Klivira's platform is specifically designed to address the unique operational constraints of oncology prior authorization. From EMR-side detection at order entry using CDS Hooks to intelligent routing across medical and pharmacy benefits, our solution minimizes administrative burden and accelerates treatment initiation. We prioritize regimen-level PA workflows and integrate with peer-to-peer scheduling to streamline clinical-necessity reviews.

Klivira's Oncology Automation Capabilities

NCCN-compendium-aware policy logic to surface required documentation per regimen and tumor type
Regimen-level PA workflow that bundles related components for submission where supported by the payer
Automated medical-vs-pharmacy benefit routing for oral oncolytics versus IV infusions via appropriate channels (PBM or medical PA)
Concurrent PA tracking for dozens of events per patient, including supportive-care and surveillance imaging PAs
Integration with peer-to-peer scheduling for efficient oncologist-payer reviews on clinical-necessity denials
Real-time status tracking and approval write-back to the EMR to ensure downstream claim accuracy

Seamless Integration with EMRs and Payer Channels

Klivira integrates deeply with major EMR systems via SMART on FHIR, CDS Hooks, and HL7 v2, ensuring PA requirements are identified at the point of order. Our platform utilizes industry standards like Da Vinci CRD, DTR, and PAS, alongside X12 278, provider portal APIs, and fax fallback, to ensure comprehensive connectivity across all payer types. This robust integration facilitates compliance with mandates like CMS-0057-F, ensuring timely decisions for Medicare Advantage and Medicaid managed care plans.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit PAs for oncology drugs?

Klivira's system intelligently routes prior authorization requests based on the benefit category. For provider-administered IV oncology drugs (medical benefit), requests are sent via payer portals or X12 278. For oral oncolytics (pharmacy benefit), requests are routed through the payer's PBM and ePA partners like CoverMyMeds or Surescripts, ensuring the correct channel is always used.

Can Klivira manage prior authorizations for complex multi-agent chemotherapy regimens?

Yes, Klivira supports regimen-level prior authorization workflows. Our platform is designed to bundle multiple agents (e.g., chemotherapy + targeted therapy + immunotherapy) into a single submission where the payer supports it, or manage separate submissions efficiently when required. This streamlines the complex process of authorizing multi-drug oncology protocols.

What role do NCCN Guidelines play in Klivira's oncology PA automation?

Klivira's policy engine is NCCN-compendium-aware. It leverages NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium to inform documentation requirements, validate medical necessity, and identify appropriate off-label uses. This ensures that submitted prior authorization requests align with widely accepted clinical standards, reducing denial rates.

How does Klivira address the urgency of prior authorizations in aggressive cancer types?

Klivira minimizes delays by detecting PA requirements at the point of order entry using EMR-side CDS Hooks. This proactive approach, combined with automated documentation assembly, rapid submission via electronic channels (like Da Vinci PAS), and real-time status tracking, significantly reduces the diagnosis-to-treatment interval for urgent oncology cases.

Does Klivira assist with peer-to-peer reviews for oncology clinical necessity denials?

Yes, Klivira integrates peer-to-peer scheduling into the denial management workflow. When a clinical-necessity denial requires an oncologist-payer discussion, our system facilitates the scheduling and routing of these reviews, ensuring timely engagement from clinical staff and supporting the appeal process effectively.